NTV Asset Management LLC Has $1.44 Million Holdings in Medtronic plc (NYSE:MDT)

NTV Asset Management LLC lessened its holdings in shares of Medtronic plc (NYSE:MDT) by 1.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,082 shares of the medical technology company’s stock after selling 208 shares during the quarter. NTV Asset Management LLC’s holdings in Medtronic were worth $1,444,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Catalyst Capital Advisors LLC grew its stake in Medtronic by 1.4% during the 4th quarter. Catalyst Capital Advisors LLC now owns 29,325 shares of the medical technology company’s stock valued at $2,342,000 after acquiring an additional 405 shares in the last quarter. Americana Partners LLC grew its stake in Medtronic by 5.8% during the 4th quarter. Americana Partners LLC now owns 6,884 shares of the medical technology company’s stock valued at $550,000 after acquiring an additional 379 shares in the last quarter. Financiere des Professionnels Fonds d investissement inc. grew its stake in Medtronic by 10.4% during the 4th quarter. Financiere des Professionnels Fonds d investissement inc. now owns 139,042 shares of the medical technology company’s stock valued at $11,107,000 after acquiring an additional 13,051 shares in the last quarter. Capital Performance Advisors LLP grew its stake in Medtronic by 68.2% during the 4th quarter. Capital Performance Advisors LLP now owns 4,638 shares of the medical technology company’s stock valued at $370,000 after acquiring an additional 1,881 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new position in Medtronic during the 4th quarter valued at about $219,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In other news, EVP Brett A. Wall sold 9,850 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $80.41, for a total transaction of $792,038.50. Following the completion of the transaction, the executive vice president now directly owns 40,708 shares in the company, valued at $3,273,330.28. The trade was a 19.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. lowered their target price on Medtronic from $99.00 to $96.00 and set a “neutral” rating on the stock in a research note on Friday, November 15th. Robert W. Baird lowered their price target on Medtronic from $96.00 to $93.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Wells Fargo & Company lowered their price target on Medtronic from $106.00 to $98.00 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Sanford C. Bernstein boosted their price target on Medtronic from $96.00 to $97.00 and gave the company an “outperform” rating in a research note on Wednesday, November 20th. Finally, Truist Financial lowered their price target on Medtronic from $93.00 to $89.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $95.00.

Medtronic Stock Up 0.9 %

MDT opened at $93.02 on Monday. The business has a 50 day moving average price of $85.51 and a 200 day moving average price of $86.86. Medtronic plc has a twelve month low of $75.96 and a twelve month high of $93.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.39 and a current ratio of 1.84. The firm has a market cap of $119.28 billion, a P/E ratio of 28.45, a price-to-earnings-growth ratio of 2.57 and a beta of 0.84.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The firm had revenue of $8.40 billion during the quarter, compared to analyst estimates of $8.27 billion. During the same period in the previous year, the company earned $1.25 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Research analysts forecast that Medtronic plc will post 5.45 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 10th. Stockholders of record on Friday, December 27th were issued a dividend of $0.70 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.01%. Medtronic’s dividend payout ratio (DPR) is presently 85.63%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.